Opus Genetics Inc (IRD) concluded trading on Thursday at a closing price of $1.02, with 9.48 million shares of worth about $9.67 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 4.24% during that period and on June 26, 2025 the price saw a gain of about 5.13%. Currently the company’s common shares owned by public are about 45.48M shares, out of which, 29.40M shares are available for trading.
Stock saw a price change of 9.52% in past 5 days and over the past one month there was a price change of 0.00%. Year-to-date (YTD), IRD shares are showing a performance of -36.25% which decreased to -14.29% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.65 but also hit the highest price of $2.18 during that period. The average intraday trading volume for Opus Genetics Inc shares is 882.87K. The stock is currently trading 3.51% above its 20-day simple moving average (SMA20), while that difference is up 8.05% for SMA50 and it goes to -6.02% lower than SMA200.
Opus Genetics Inc (NASDAQ: IRD) currently have 45.48M outstanding shares and institutions hold larger chunk of about 22.78% of that.
The stock has a current market capitalization of $60.85M and its 3Y-monthly beta is at -0.01. It has posted earnings per share of -$1.94 in the same period. It has Quick Ratio of 1.98 while making debt-to-equity ratio of 3.72. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IRD, volatility over the week remained 6.60% while standing at 9.95% over the month.
Stock’s fiscal year EPS is expected to rise by 59.53% while it is estimated to increase by 23.56% in next year. EPS is likely to grow at an annualized rate of 32.46% for next 5-years, compared to annual growth of 24.32% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Craig Hallum on April 11, 2025 offering a Buy rating for the stock and assigned a target price of $6 to it. Coverage by H.C. Wainwright stated Opus Genetics Inc (IRD) stock as a Buy in their note to investors on November 13, 2024, suggesting a price target of $8 for the stock.
